Paul Industries builds controlled processing environments across Iowa. The question that catches ingredient plants out is what happens when a customer is a pharmaceutical manufacturer. Corn-derived materials including starches and sugars are used as pharmaceutical excipients, and an excipient is not a food ingredient with a different label on it. The customer is operating under a regulatory framework that expects things of its suppliers, and those expectations land on the plant that made the material.
Request a quote or call 201-450-8280
The material did not change; the supply chain did
A starch or a sugar going into a tablet is chemically the same material as one going into a food product. What differs is that the pharmaceutical manufacturer has to know and control what goes into its product, and cannot simply assert that an incoming excipient is suitable. It has to demonstrate it, and the way it demonstrates it is largely by auditing you.
That produces a set of expectations that an ingredient plant may never have faced, and they are mostly about evidence rather than about equipment.
Segregation and traceability. Which line made this lot, what else that line made before it, and how the plant knows. A facility that can answer that from records rather than from recollection is in a very different position during an audit.
Cleaning evidence. The continuous-process reasoning that legitimately covers the rest of a wet mill does not satisfy a pharmaceutical customer for a line serving them. They will want a cleaning approach with a stated basis and evidence that it was executed, which is a different standard from the one a food ingredient line has had to meet.
Change control. Whether a change to the process or the equipment was assessed and recorded, because a customer relying on the material needs to know it is the same material as the one they qualified.
Specification and testing. What the material is tested against and how the result is retained.
What is frequently not required is an ISO-classified cleanroom. The excipient is generally not sterile, the process is not aseptic, and classification addresses airborne particulate contaminating a vulnerable product. Building a classified suite in response to a pharmaceutical customer is a common and expensive misreading of what the customer actually asked for, which is evidence and control rather than a particle count.
What the same plant needs for different customers
| Food ingredient | Pharmaceutical excipient | |
|---|---|---|
| Driven by | Food safety framework and customer specification | Customer’s own regulatory obligations |
| Cleaning basis | Continuous process reasoning is often adequate | Stated basis with execution evidence |
| Traceability | Lot level | Lot level, with what preceded it on the line |
| Change control | Internal | Assessed, recorded and frequently notified |
| Audit | Periodic, by customers and authorities | More frequent and more document-focused |
| Classified environment | No | Usually not; controlled and evidenced instead |
| Continuous load | Per year | Over ten years |
|---|---|---|
| 20 kW | $11,914 | $119,140 |
| 40 kW | $23,827 | $238,270 |
| 80 kW | $47,654 | $476,540 |
Where a controlled environment genuinely helps
Although classification is usually unnecessary, there is a place in an ingredient plant where environmental control earns its keep, and it is the end of the line rather than the process.
Drying, milling, blending and packing handle finished material in a form that is dry, fine and exposed. That is where contamination that reaches the product does so without any subsequent step to remove it, and it is also where the environment is most controllable. A properly built controlled area at that stage, meaning filtered air with a designed pressure relationship to dirtier spaces, cleanable surfaces, and controlled personnel and material routes, addresses a real risk at moderate cost.
It is worth noting what that area is up against, because it connects to the rest of this site’s dry-plant pages. Finished starch and sugar in powder form are dusty, dust travels, and cross-contamination between products in a multi-product packing hall is a genuine risk. Many such powders are also combustible, which brings the dust hazard analysis obligations discussed on our Utah page into an Iowa packing area just as firmly.
So the sensible sequence for an Iowa plant acquiring a pharmaceutical customer is: establish the evidence and control expectations first, because that is what the customer is actually asking for; build or improve a controlled area at the packing end, because that addresses the real contamination exposure; and resist building a classified suite unless somebody can explain what particle limit is being met and why.
Frequently asked questions
Do you build controlled environments for Iowa ingredient plants?
Yes, across the wet milling and food processing corridor and statewide: controlled packing and blending areas, filtered air with designed pressure relationships, cleanable finishes, dust containment and the utilities around them. We establish what your customer actually requires before recommending a specification.
What changes when a customer is a pharmaceutical manufacturer?
Not the material, the evidence. They have to demonstrate control over what goes into their product and they do so largely by auditing you, so expectations land on segregation and traceability, cleaning with a stated basis and execution evidence, change control, and specification and testing records.
Do we need a cleanroom?
Usually not. The excipient is generally not sterile, the process is not aseptic, and ISO classification addresses airborne particulate contaminating a vulnerable product. Building a classified suite in response to a pharmaceutical customer is a common and expensive misreading of a request that was actually about evidence and control.
Where should we invest instead?
In the evidence, and in a controlled area at the packing end. Drying, milling, blending and packing handle finished material in a dry, fine, exposed form with nothing downstream to remove contamination, so that is where environmental control addresses a real risk at moderate cost.
Is our continuous-process cleaning argument enough?
For the rest of the plant it may be entirely sound. For a line serving a pharmaceutical customer it generally is not, because they will want a cleaning approach with a stated basis and evidence it was executed. That is a different standard from the one a food ingredient line has previously had to meet.
What traceability will be expected?
Which line made a given lot, what that line made before it, and how the plant knows, answered from records rather than recollection. A facility that can produce that from its systems is in a materially better position during an audit than one reconstructing it, and building the capability is easier before the audit than during it.
Does dust matter in the packing area?
Yes, on two counts. Finished starch and sugar powders are dusty and dust travels, so cross-contamination between products in a multi-product packing hall is a real risk. Many such powders are also combustible, which brings dust hazard analysis obligations into the packing area as firmly as anywhere else in the plant.
How should the controlled area be specified?
Filtered air with a designed pressure relationship to dirtier spaces, cleanable non-shedding surfaces with coving and sealed penetrations, controlled personnel and material routes, and dust containment at the points where powder becomes airborne. That is provision without classification, and it is what the risk actually calls for.
Does Iowa energy cost affect the decision?
Helpfully. At 6.80 cents per kilowatt-hour against a national average of 8.13 (EIA, 2024), a 40 kW continuous air handling load for a controlled packing area is about $23,827 a year. That makes doing the useful thing affordable, and it is a far better use of money than the classified suite that was never required.
How do I get a quote for an Iowa project?
Use the form on this page or call 201-450-8280. Useful inputs are which products serve pharmaceutical customers, what those customers have asked for in writing, how packing and blending are currently arranged, whether the area handles multiple products, and whether a dust hazard analysis exists.
What does an excipient GMP audit look for?
The auditor reviews the plant against a pharmaceutical excipient GMP framework, commonly the IPEC-PQG guide or the equivalent, looking at quality management, change control, traceability, contamination control and the areas where the material is exposed. The plant's food safety system covers part of it; the rest has to be added.
Where in a wet mill is the product exposed to the environment?
Mainly at the dry end: dryers, cooling, milling, screening, conveying and packing. Upstream the material is in closed wet process, so the controlled environment effort concentrates on the dry finishing and packing area.
What air handling and finishes does an excipient packing room need?
Filtered supply air with positive pressure to adjacent areas, smooth cleanable finishes on walls, floors and ceilings, and dust control at the packing head, without necessarily meeting a cleanroom classification. The customer's specification sets whether a class is required; most ask for controlled, not classified.
How is a lot defined for a product that never stops flowing?
By time or by quantity, with the process conditions and test results for that interval recorded against the lot number, and with the interval short enough that a problem can be isolated to a bounded quantity. The lot definition is agreed with the customer and written into the quality agreement.
Does the plant need change control for excipient customers?
Yes. Changes to raw materials, process, equipment and cleaning that could affect the excipient have to be assessed and, where significant, notified to the customer. That is a quality system requirement, and the controlled area design supports it by making changes visible.
How is airborne dust controlled at an excipient packing head?
With local extraction at the filling point, enclosed transfer from the silo to the packer, and housekeeping that removes settled dust before it is re-entrained. Dust control protects the product, the packing area's cleanliness and the plant's combustible dust compliance at the same time.
What separates the excipient line from feed and industrial product lines?
Physical separation of the packing areas, dedicated or verified-clean equipment, and controlled transfer between them. Where a plant packs pharmaceutical, food and feed grades of the same material, the excipient line is the most protected.
How does allergen control apply to corn-derived excipients?
Corn is not a major allergen, but plants that also handle wheat or soy have to control cross-contact, and pharmaceutical customers ask about it. Segregation and documented cleaning cover the question.
What environmental monitoring does an excipient area need?
Monitoring appropriate to the material's risk: surface and air sampling for the organisms of concern, typically Salmonella and indicator organisms in a dry area, and records that show the control is working over time.
Can a food-grade packing area be upgraded to excipient standard?
Usually. Filtration, pressurisation, access control, finishes and dust extraction can be added, and the quality system documentation is written around the upgraded area. The larger effort is often the quality system rather than the room.
What about biorefinery products going into pharmaceutical use?
Products such as dextrose, sorbitol and other corn derivatives used as excipients carry the same expectations, and plants supplying them are audited in the same way. The controlled area requirement follows the product's exposure to the environment.
How does the customer's supplier qualification affect the timeline?
Qualification can take months, with an audit, document review and often trial lots. Building the controlled area early, so that the audit sees a working system, shortens the qualification and secures the business sooner.
What evidence of environmental control does a pharmaceutical customer accept?
A written specification for the packing area, records showing it was met, monitoring results, and a change control that covers the room, which together demonstrate control without a formal ISO classification certificate. A certificate is required only where the customer's specification names a class.
How is water controlled in the excipient area?
The dry finishing area is kept dry, with wet cleaning confined and controlled and any water event treated as an incident. Water used in the process upstream is controlled to the specification the material requires.
What is the commonest gap when an Iowa plant first supplies a pharmaceutical customer?
Documentation. The physical control is often adequate; what is missing is the change control, lot traceability and monitoring records that a pharmaceutical auditor expects to see. The room is built to make those records easy to generate.
Supplying a pharmaceutical customer from an Iowa plant?
Send us what the customer has asked for in writing. It usually is not a cleanroom. Call 201-450-8280 or use the form below.